SAB Biotherapeutics, Inc. SABS

SABS Company Overview

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibody therapeutics using genetically engineered cattle and its proprietary DiversitAb platform. The company operates within the biotechnology and immunotherapy industries, with a primary focus on immune system modulation, infectious diseases, autoimmune disorders, and oncology-related applications. SAB’s core business model centers on generating fully human polyclonal antibodies designed to provide broader epitope coverage than traditional monoclonal antibody therapies. Its lead programs have included therapeutic candidates targeting Type 1 diabetes and other immune-mediated conditions.

The company traces its origins to research conducted at South Dakota State University and was founded in 2014 following earlier scientific development efforts involving transchromosomic bovines capable of producing fully human antibodies. SAB later became publicly traded through a merger with a special purpose acquisition company in 2021. The company’s strategic positioning is based on its differentiated antibody-production platform, which aims to combine the specificity of biologics with broader immune targeting capabilities. Public disclosures in SEC filings and investor materials consistently identify the DiversitAb technology platform and transchromosomic cattle infrastructure as the company’s principal competitive differentiators.